Holen Sie sich die Stockscreener-App
26.13
3.49%
0.88
Handel nachbörslich:
26.13
Schlusskurs vom Vortag:
$25.25
Offen:
$25.7
24-Stunden-Volumen:
996.63K
Relative Volume:
0.71
Marktkapitalisierung:
$3.32B
Einnahmen:
$24.05M
Nettoeinkommen (Verlust:
$-243.33M
KGV:
-8.7088
EPS:
-3.0004
Netto-Cashflow:
$-370.18M
1W Leistung:
+8.78%
1M Leistung:
+11.81%
6M Leistung:
+471.77%
1J Leistung:
+493.86%
1-Tages-Spanne:
$25.27
$26.33
1-Wochen-Bereich:
$22.84
$26.46
52-Wochen-Spanne:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
26.13 | 3.21B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
ALMS Earnings History & Surprises | EPS & Revenue Results | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis Inc: Year-End 2025 Financial Results and Strategic TYK2 Pipeline Outlook - AlphaStreet
Why is ALMS stock rising today? - MSN
ALMS Price Today: Alumis Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Why Alumis Inc. Stock Is Surging Higher Now - TipRanks
ALMS Financials: Income Statement, Balance Sheet & Cash Flow | Alumis Inc - Stock Titan
Why Alumis Inc. Shares Are Surging Today - TipRanks
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 25.3% in March - MarketBeat
Saturn V Capital Management LP's Alumis Inc(ALMS) Holding History - GuruFocus
Morgan Stanley Resumes Coverage of Alumis (ALMS) with $23 PT - MSN
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target - TipRanks
H.C. Wainwright reiterates Alumis stock rating, $25 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Alumis stock rating, $25 target - Investing.com
H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $25 - Moomoo
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Raymond James and Guggenheim stay bullish on Alumis (ALMS) after trial results - MSN
Quarterly Earnings: Is Alumis Inc in a consolidation phaseProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
Alumis Inc. $ALMS Shares Sold by Trium Capital LLP - MarketBeat
How Investors Are Reacting To Alumis (ALMS) Psoriasis Drug’s Strong Phase 3 Data And Safety Profile - simplywall.st
ALUMIS INC. unveils psoriasis treatment isolating effects to immune cells only - Traders Union
Deep Track files Schedule 13G reporting 7.36M shares in ALMS (ALMS) - Stock Titan
Risk Analysis: Is Alumis Inc gaining market shareQuarterly Profit Review & High Return Trade Opportunity Guides - baoquankhu1.vn
Alumis Inc. (ALMS) stock price, news, quote and history - Yahoo Finance UK
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results - Yahoo Finance
Alumis (NASDAQ:ALMS) Shares Down 4.1%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Dropping After Good News - TipRanks
Form 8-KCurrent report - ADVFN
Why is Alumis stock falling Monday? - MSN
10 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Alumis (ALMS) Is Down 5.8% After Positive Phase 3 Psoriasis Data And NDA Plans - Yahoo Finance
Alumis (ALMS) Valuation Check After Positive Phase 3 Psoriasis Results For Envudeucitinib - Yahoo Finance
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Why Alumis (ALMS) Is Down 8.4% After Positive Phase 3 Psoriasis Data And FDA Filing Plans - Sahm
ALMS SEC FilingsAlumis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why Alumis Inc. Shares Are Suddenly Surging - TipRanks
HC Wainwright Brokers Raise Earnings Estimates for Alumis - marketbeat.com
Alumis (NASDAQ:ALMS) Trading 12.1% Higher Following Analyst Upgrade - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Alumis Inc. (ALMS), Aquestive Therapeutics (AQST) - The Globe and Mail
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases - BioSpace
FY2027 Earnings Estimate for Alumis Issued By HC Wainwright - MarketBeat
Alumis Furthers Its Case In TYK2 Race With Phase III Envudeucitinib Data - Citeline News & Insights
Oppenheimer Raises Price Target for ALMS, Maintains Outperform R - gurufocus.com
Alumis (ALMS): HC Wainwright & Co. Lowers Price Target, Maintains Buy Rating | ALMS Stock News - GuruFocus
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):